Navigation Links
Galderma Completes Tender Offer for CollaGenex
Date:4/7/2008

More than 97% of CollaGenex common stock tendered (including guaranteed

deliveries)

LAUSANNE, Switzerland, April 7, 2008 /PRNewswire/ -- Galderma Pharma S.A., a global specialty pharmaceutical company focused on dermatology, today announced that its U.S. holding company, Galderma Laboratories, Inc., has completed its all cash tender offer for CollaGenex Pharmaceuticals, Inc. (Nasdaq: CGPI). The tender offer expired at 12:00 Midnight, New York City time, at the end of Friday, April 4, 2008.

As of such time, an aggregate of approximately 21 million shares of CollaGenex common stock (including approximately 1.3 million shares that were tendered pursuant to the guaranteed delivery procedures) have been tendered into, and not withdrawn from, the offer. The tendered shares represent approximately 97% of the outstanding shares of CollaGenex. All of such shares have been accepted in accordance with the terms of the tender offer and upon Galderma Laboratories' acquisition of such shares, CollaGenex will become a majority owned subsidiary of Galderma Laboratories.

Galderma Laboratories expects that, shortly after the acquisition of such shares, it will complete the merger of its wholly owned subsidiary, Galderma Acquisition Inc., and CollaGenex. As a result of the merger, each outstanding share of CollaGenex common stock will be converted into the right to receive $16.60 per share in cash, without interest, and CollaGenex will become a wholly owned subsidiary of Galderma Laboratories.

About Galderma

Galderma, created in 1981 as a joint venture between Nestle and L'Oreal, is a fully integrated specialty pharmaceutical company dedicated exclusively to the field of dermatology. The Com
'/>"/>

SOURCE Galderma Pharma S.A.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Galderma Announces HSR Clearance for Its Proposal to Acquire CollaGenex Pharmaceuticals
2. ZARS Pharma Announces Worldwide License Agreement With Galderma Pharma S.A. for Pliaglis(TM), a Topical Local Anesthetic
3. Galderma Pharma, S.A. and ZARS Pharma, Inc. Extend Agreement to Cover Worldwide Rights for Pliaglis(TM)
4. Galderma Reaches Agreement to Acquire CollaGenex Pharmaceuticals
5. Galderma Associates Itself to Cartiers Womens Initiative Awards to Recognize Female Entrepreneurs From Around the Globe
6. ProGenTech Completes $21 Million Series C Financing
7. KV Pharmaceutical Company Completes Financial Restatement with the Filing of Fiscal 2007 Form 10-K
8. Payformance Completes Sale of Corporate Payments Division
9. PreMD Inc. Completes Debenture Financing
10. Gentiva(R) Health Services Completes Acquisition of Major Home Health Provider in CON State of Mississippi
11. Roche Completes Tender Offer for Ventana Shares
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... 2015 WellCare Health Plans, Inc. (NYSE: WCG) ... by the Florida Healthy Kids Corporation (FHKC) to continue to ... as part of the Florida Healthy Kids (FHK) program. Pending ... and may be extended for two additional years at FHKC’s ... in the FHK program who live in Regions 1, 2, ...
(Date:5/21/2015)... May 21, 2015 Ticket Down is a reliable ... USA vs. Guatemala on Friday, July 3rd at LP ... to become a fan of international soccer. The number of chances ... on American soil is growing at a large clip. Over the ... come to the USA to play in front of the American ...
(Date:5/21/2015)... Bird B Gone, the leader in bird ... new sizes of the Bird Spike 2001 to its comprehensive ... bird spike is specifically designed to reduce building maintenance ... lines, parapet walls, I-beams, window ledges and more. It is ... boxes, allowing customers to buy the right amount of spike ...
(Date:5/21/2015)... Amercanex today announced that it is ... electronic marketplace for industrial hemp and associated products. ... which wholesale and retail distributors of hemp can ... a fully disclosed and transparent environment. , Amerhempex ... unique blend of cutting-edge infrastructure, tools, and needs-based ...
(Date:5/21/2015)... (PRWEB) May 21, 2015 Shimadzu ... AOC-6000 robotic autosampler, which features new time-saving tools ... standard injection techniques: liquid, headspace, and solid-phase microextraction ... This new tool allows users to seamlessly change ... the GC/MS. , The new autosampler allows for ...
Breaking Medicine News(10 mins):Health News:WellCare Selected to Continue Participating in the Florida Healthy Kids Program, Will Serve Nine Florida Regions Under the New Contract 2Health News:USA vs. Guatemala Tickets: Ticket Down Slashes United States Men's Soccer Team (USMNT) vs. Guatemala Tickets at LP Field in Nashville on 7/3/15 2Health News:Bird B Gone, Inc. Offers New Box Sizes of Stainless Steel Bird Spikes 2Health News:Bird B Gone, Inc. Offers New Box Sizes of Stainless Steel Bird Spikes 3Health News:Amercanex is Revolutionizing Order and Efficiency in the Hemp Industry 2Health News:Shimadzu’s New AOC-6000 Autosampler Makes Automated Sample Introduction Simple and Efficient 2
... for Parkinson,s Research announced awards totaling approximately $10.1 million ... development projects. The funding includes $2.5 million to drive ... one of the Foundation,s Edmond J. Safra Core Programs ... Clinical Intervention Awards are: , Charlotte Keywood, Addex ...
... HealthDay Reporter , TUESDAY, Oct. 5 (HealthDay News) ... who received ,hands-only, cardiopulmonary resuscitation (CPR) from a bystander ... who received no CPR or conventional CPR with mouth-to-mouth ... not only is ,hands-only, CPR -- in which the ...
... Saint Louis University researcher, scientists have identified an important microRNA ... blood. Led by ngel Baldn, Ph.D., assistant professor ... published in a recent issue of Proceedings of the ... America, the study found that the microRNA miR-33, may ...
... The National Institutes of Health has awarded a ... Florida and Tampa-based biotechnology company Saneron-CCEL Therapeutics, Inc., ... human umbilical cord blood cells (HUBC) into animal ... use the pre-clinical data to gain U.S. Food ...
... Oct. 5, 2010 Only about a third of ... recommendations, which means they are likely missing out ... Along with vitamins, minerals and fiber, fruits and vegetables ... suggests help support women,s health including breast and ovarian ...
... 2010 Elsevier, the leading publisher of scientific, ... announced a new version of its online research ... was well received by the neuroscience researcher community ... In the updated version, BrainNavigator 3.0, Elsevier has ...
Cached Medicine News:Health News:MJFF announces over $10 million in funding for clinical and pre-clinical PD research 2Health News:'Hands-Only' CPR May Work Best for Cardiac Arrest 2Health News:'Hands-Only' CPR May Work Best for Cardiac Arrest 3Health News:'Hands-Only' CPR May Work Best for Cardiac Arrest 4Health News:Better cholesterol drugs may follow Saint Louis University researcher's breakthrough 2Health News:USF and Saneron get $2.6 million to develop Alzheimer's treatment using umbilical cord blood cells 2Health News:Shortfalls in carotenoid intake may impact women's health 2Health News:Shortfalls in carotenoid intake may impact women's health 3Health News:Shortfalls in carotenoid intake may impact women's health 4Health News:Elsevier's BrainNavigator 3.0 reflects the next step in enhancing neurological research 2Health News:Elsevier's BrainNavigator 3.0 reflects the next step in enhancing neurological research 3
(Date:5/21/2015)... May 21, 2015 Thirteen winners of ... designed to bring promising medical inventions to market, ... (HPN) in collaboration with the National Institutes of ... (CAI).  The winning teams were selected based on ... and will move forward to phase three of ...
(Date:5/21/2015)...  AbbVie (NYSE: ABBV ) announced today the ... announced offer to acquire each outstanding share of common ... cash and AbbVie common stock, as described in the ... and Exchange Commission by AbbVie on March 23, 2015, ... offer will expire at 5:00 p.m., New ...
(Date:5/21/2015)... Delcath Systems, Inc. (NASDAQ: DCTH ) ... its expanded Global Phase 2 Clinical Trial Program of ... unresectable hepatocellular carcinoma (primary liver cancer, or HCC) has ... conducted at the same hospitals in Europe ... trial, and ICC enrollment is now open at Goethe ...
Breaking Medicine Technology:Neuro Startup Challenge selects 13 winning teams to launch startups for unlicensed NIH technologies to improve brain health 2Neuro Startup Challenge selects 13 winning teams to launch startups for unlicensed NIH technologies to improve brain health 3Neuro Startup Challenge selects 13 winning teams to launch startups for unlicensed NIH technologies to improve brain health 4AbbVie Announces Offer Consideration for Acquisition of Pharmacyclics 2AbbVie Announces Offer Consideration for Acquisition of Pharmacyclics 3AbbVie Announces Offer Consideration for Acquisition of Pharmacyclics 4ICC Cohort Of Delcath's Global Phase 2 Trial Of Melphalan/HDS In Hepatocellular Carcinoma Now Open For Enrollment 2ICC Cohort Of Delcath's Global Phase 2 Trial Of Melphalan/HDS In Hepatocellular Carcinoma Now Open For Enrollment 3ICC Cohort Of Delcath's Global Phase 2 Trial Of Melphalan/HDS In Hepatocellular Carcinoma Now Open For Enrollment 4
... 18 Aida,Pharmaceuticals, Inc. (OTC Bulletin Board: AIDA) ... is developing a potential cancer drug,that seeks to ... a pre-clinical product being developed by Aida,s Shanghai,Qiaer ... the,function of extracted fragments of Vasostatin, an inhibitor ...
... CARLSBAD, Calif., April 18 Isis,Pharmaceuticals, Inc. ... of two studies,designed to assess the impact ... Annual Atherosclerosis, Thrombosis and Vascular Biology (ATVB),Conference ... in a poster,entitled "Antisense Inhibition of Apolipoprotein ...
Cached Medicine Technology:Aida Announces New Anti-Cancer Drug Under Development 2Isis Reports Reduction of apoB-100 Levels in a Murine Model Resulting in Up to 92% Reduction of Atherosclerosis 2Isis Reports Reduction of apoB-100 Levels in a Murine Model Resulting in Up to 92% Reduction of Atherosclerosis 3Isis Reports Reduction of apoB-100 Levels in a Murine Model Resulting in Up to 92% Reduction of Atherosclerosis 4
... IMPACs comprehensive information system designed specifically ... integrate and streamline their diagnostic, management, ... intuitive software solution. Thousands of laboratory ... have proven PowerPaths unique "case-centric model ...
The most compact revolutionary innovation in hematology. 26 paramaters with 5 part DIFF....
... The remote vision controls ... NP-3S chart projector from the ... the autorefraction measurements can be ... via wireless data transfer. The ...
... (threshold) testing provides clinically beneficial information ... conditions. Dark adaptometry is useful in ... degenerations, senile miosis, high myopia, vitamin-A ... while whole-field scotopic sensitivity has been ...
Medicine Products: